The initial results are expected before the end of May, 2008. These animal studies will be conducted by Krishna Menon, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.
Eugene Seymour, CEO of NanoViricides, said: “The purpose of this initial study is twofold: To assess therapeutic efficacy and to determine the appropriate dosages of drug that should be used in the later animal study. If initial performance goals are met, it will be a critical first step in validating the company’s HivCide-I as a potential treatment for HIV/AIDS.”